We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Spells Out Development of Recurrent Herpes Labialis Therapies
FDA Spells Out Development of Recurrent Herpes Labialis Therapies
The FDA is providing recommendations on clinical trial designs for sponsors developing antiviral drugs to prevent and treat recurrent herpes labialis, or herpes-related sores that form around the mouth.